| Today’s Big NewsJun 23, 2025 |
| By Nick Paul Taylor The effect of Novo Nordisk’s amycretin injections on body weight showed no signs of plateauing after 36 weeks, suggesting the Danish drugmaker can improve on the data that triggered a jump in its share price early this year. However, the tolerability data raised questions about the strength of Novo’s hand. |
|
|
|
By James Waldron Having secured one of last year’s largest funding rounds, AI-focused Formation Bio is now eyeing up to 545 million euros ($626 million) from a licensing deal with Sanofi. |
By James Waldron Compass Pathways' delayed phase 3 readout for its psilocybin treatment has hit its primary endpoint of reducing the severity of patients’ depression, but investors appear unimpressed. |
Sponsored by AstraZeneca BIO 2025 showed the science is ready—now it’s time to ensure access, equity, and impact for patients. |
|
Immune cell engagers are opening new avenues in immuno-oncology. Discover how single-cell analysis is enabling smarter, faster ICE discovery. Watch now
|
|
By James Waldron Aiming T-cell engagers at autoimmune diseases continues to be a red-hot dealmaking target, as evidenced by Otsuka Pharmaceutical’s decision to pay $47 million upfront for the ex-China rights to Harbour BioMed’s BCMAxCD3 bispecific candidate. |
By Nick Paul Taylor A combination featuring Exelixis’ zanzalintinib has beaten Bayer’s Stivarga in a phase 3 trial. The overall survival win moves Exelixis a step closer to its ambition of turning the oral tyrosine kinase inhibitor into a $5 billion-a-year product. |
By James Waldron Leap Therapeutics is expanding its layoff plans to encompass three-quarters of its staff while scrapping its sole clinical trial. |
By James Waldron Vertex Pharmaceuticals may have narrowed its focus this year, but the biopharma’s decision to stick with its remaining islet cell therapy appears to be paying off so far. |
By Nick Paul Taylor The 85th American Diabetes Association Scientific Sessions have shown the depth of China’s play for the GLP-1 market, with Corxel Pharmaceuticals and Sciwind Biosciences among the companies to share data at the event. |
By Fraiser Kansteiner Lilly provided a comprehensive look at positive results from a group of studies that assessed the company's once-a-week insulin candidate efsitora in multiple Type 2 diabetes patient populations. Lilly says it plans to submit its efsitora package to global regulators by the end of the year. |
By Angus Liu Roche has demonstrated the power of combining two of oncology's hottest modalities—bispecifics and antibody-drug conjugates—in a Lunsumio-Polivy regimen in large B-cell lymphoma. |
By Paige Minemyer Insurers large and small from across the country have announced a series of commitments they're making to reform one of the biggest pain points in the patient journey: prior authorization. |
By Conor Hale Illumina is diving deeper into proteomics research with a $425 million plan to acquire SomaLogic, including its protein analysis platforms and certified lab services business. |
Fierce podcastsDon’t miss an episode |
| | This week on "The Top Line," AbbVie’s Daejin Abidoye, M.D., joins us to discuss the future of antibody drug conjugates. |
|
|---|
|
|
|
Thursday, July 10, 2025 | 10am ET / 7am PT The transition from drug discovery to process development poses significant challenges. Join us for this deep dive into how adopting a collaborative approach between medicinal and process chemistry teams can help address key obstacles and accelerate progress from discovery to early clinical milestones. Register now.
|
|
| Executive SummaryBiotech innovation doesn’t slow down—and neither should your lab partner. This brief outlines how early scientific engagement, operational transparency, and integrated global lab services help reduce risk, stay on schedule, and deliver results. Whether you're navigating your first trial or scaling a growing pipeline, see how a purpose-built lab model can help you move smarter and faster. Sponsored by: IQVIA Laboratories |
| WhitepaperWe analyzed ~300 launches to identify the factors most correlated with commercial success & built a framework for peak go-to-market performance. Presented by Blue Matter, strategic consultants in the life sciences |
| |
|
